Chimeric Defensin Proteins for Cancer Vaccines
Available for licensing is a fusion protein vaccine comprising a defensin peptide fused to a tumor antigen to elicit an immune response effective in treating cancer.
Humans are particularly vulnerable to cancer as a result of an ineffective immunogenic response. Tumor antigens are known to be poorly immunogenic and attempts to elicit immune responses against the antigens specific to tumor cells have been largely unsuccessful. The inventors have developed a cancer vaccine comprising a defensin peptide fused to a tumor antigen to enhance the immunogenicity of the tumor antigen. The inventors have demonstrated in an animal model that chimeric defensing proteins fused to a lymphoma antigen generate a measurable anti-tumor cellular immune response.
|Potential Commercial Applications:||Competitive Advantages:||A vaccine for increasing the immunogenicity of a tumor antigen, allowing the treatment of cancer.||Can produce an in vivo immune response, resulting in the inhibition of tumor cells.|
Bira Arya (NCI)
Larry Kwak (NCI)
U.S. Pat: 7,754,676 issued 2010-07-13
U.S. Pat: 7,915,040 issued 2011-03-29
U.S. Pat: 8,084,250 issued 2011-12-27
U.S. Pat: 8,551,936 issued 2013-10-08
US Application No. 60/233,074
U.S. Pat: 8,754,030 issued 2014-06-17
PCT Application No. PCT/US01/29074
US Application No. 14/268,949
The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize cancer vaccines comprising a defensin fused to tumor or viral antigens. For collaboration opportunities, please contact Nicole Guyton, Ph.D. at 301-435-3101 or email@example.com for more information. Click here to view the NCI collaborative opportunity announcement.
Yolanda Hawkins , Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325
Rockville , MD 20852
OTT Reference No: E-196-2000/0